eligibility_summary
Eligible: histologically confirmed unilateral primary invasive breast cancer (pT1N0M0), HER2+ (IHC 3+ or IHC 2+/FISH+ per ASCO/CAP 2018), ECOG 0–1, adequate organ function, not pregnant/breastfeeding, complete clinicopath data, able to comply and consent. Exclude: bilateral/metastatic, neoadjuvant therapy, recent other cancers (except cured CIS cervix/NMSC), severe infection/illness, HIV/HBV/HCV, drug allergy, prior systemic/radiation therapy, recent trial/live vaccine, psych/substance issues, or investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, open-label single-arm adjuvant trial in early HER2+ breast cancer testing a short course (4 cycles) of dual HER2 blockade (trastuzumab + pertuzumab) with a taxane. Trastuzumab (humanized IgG1 monoclonal antibody) binds HER2 domain IV to inhibit signaling and mediate ADCC. Pertuzumab (humanized IgG1 monoclonal antibody) binds HER2 domain II, preventing HER2/HER3 or HER2/EGFR dimerization and suppressing PI3K/AKT and MAPK pathways. Taxanes (e.g., paclitaxel/docetaxel, cytotoxic microtubule-stabilizing agents) arrest mitosis. Targets: HER2-overexpressing tumor cells, HER2/ERBB2 receptor signaling and dimerization, downstream survival/proliferation pathways, NK-cell–mediated ADCC, and microtubules in dividing cancer cells.